Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00331188|
Recruitment Status : Completed
First Posted : May 29, 2006
Last Update Posted : July 8, 2008
|Condition or disease||Intervention/treatment||Phase|
|Esophageal Varices Portal Hypertension Gastric Varices Esophageal Bleeding||Drug: Sanvar® (vapreotide)||Phase 3|
This is a single-arm open-label clinical study with historical controls using Sanvar® (vapreotide) administered for 5 days in patients with acute variceal bleeding due to portal hypertension.
Cirrhotic patients with a history of acute hematemesis and/or melena admitted to the emergency unit and meeting the eligibility criteria will receive, as soon as possible after admission (within a maximum of 24 hours after onset of hemorrhage and within 6 hours after admission), Sanvar® (vapreotide acetate) 50 µg IV bolus followed by an IV continuous infusion of 50 µg/h for 5 days.
The diagnostic and therapeutic endoscopy will be performed as soon as possible after the initiation of the study drug infusion, but no more than 12 hours after the patient's admission to the study center. A final follow up will be performed on Day 42.
Patients for whom the source of bleeding is determined at endoscopy to be due to a cause other than portal hypertension (e.g. gastric ulcer) will be replaced. In addition, in such cases the study medication will be discontinued and patients will receive standard treatment according to the cause of their bleeding. These patients will be followed up for safety only.
*Note: There is no provision in this study to have an expanded access program.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||70 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Early Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||June 2008|
|Actual Study Completion Date :||July 2008|
- To determine the efficacy of the early administration of Sanvar® (vapreotide) in association with endoscopic treatment for the control of bleeding at 5 days, i.e. control of initial bleeding and prevention of early re-bleeding, plus survival. [ Time Frame: 5 days ]
- To assess the following:
- The effect of drug administration before endoscopy assessed by the endoscopic facilitation and control of bleeding at endoscopy, [ Time Frame: Endoscopy ]
- Control of bleeding 6 hours after infusion of the study drug (= Tinf + 6h), [ Time Frame: Tinf + 6h ]
- Control of bleeding by time periods (Tendo+6h, Tendo+48h and Tendo+ 120h) by Child Pugh class, [ Time Frame: Tendo+6h, Tendo+48h and Tendo+ 120h ]
- Number of blood units administered during the 5 days of drug infusion, [ Time Frame: 5 days ]
- Safety of treatment [ Time Frame: 42 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00331188
|Study Chair:||Joseph Lim, M.D.||Yale University|
|Principal Investigator:||Tarek Hassanein, M.D.||University of California, San Diego|
|Principal Investigator:||Michael B. Fallon, M.D.||UAB Liver Center, Division of Gastroenterology & Hepatology|
|Principal Investigator:||Daniel R. Ganger, M.D.||Northwestern Memorial Hospital|
|Principal Investigator:||Naga P. Chalasani, M.D.||Indiana University School of Medicine|
|Principal Investigator:||Adrian Reuben, M.D.||Medical University of South Carolina|
|Principal Investigator:||Paul J. Thuluvath, M.D.||The Johns Hopkins Hospital & School of Medicine|
|Principal Investigator:||James F. Trotter, M.D.||University of Colorado, Denver|
|Principal Investigator:||Hugo Vargas, M.D.||Mayo Clinic Scottsdale, Arizona|
|Principal Investigator:||Samuel Sigal, M.D.||Weill Medical College of Cornell University|
|Principal Investigator:||Michele D. Bishop, M.D.||Mayo Clinic Jacksonville Florida|
|Principal Investigator:||Gary A. Abrams, M.D.||Alabama Liver & Digestive Specialists Research Center - Montgomery, AB|
|Principal Investigator:||Robert S. McFadden, M.D.||CHRISTUS Santa Rosa Medical Center - San Antonio, TX|
|Principal Investigator:||Nezam H. Afdhal, M.D.||Beth Israel Deaconess Medical Center, Boston MA|
|Principal Investigator:||Jeffrey S. Crippin, M.D.||Washington University School of Medicine|
|Principal Investigator:||Alvaro Koch, M.D.||University of Kentucky Medical Center - Lexington, KY|
|Principal Investigator:||Kimberly Beavers, M.D., M. Ph.||Mission Hospitals, Inc. - Asheville, NC|
|Principal Investigator:||Arun J. Sanyal, M.D.||Virginia Commonwealth University|